Relevance. The effect of a tissue engineering construct based on synthetic octacalcium phosphate activated with plasmid DNA with vascular endothelial growth factor gene on bone morphogenesis at the jaw defect sites of patients was studied. It is shown that the studied osteoplastic material stimulates osteosynthesis pathways already at early stages, and xenogenic hydroxyapatite, triggers osteogenesis processes with considerable delay and does not have time to form a full-fledged bone structure by 6 months.Aim. Evaluate the dynamics of reparative osteogenesis based on the results of histomorphometric diagnostics in patients with defects in the jaw bones of various configurations and lengths with an implanted bone matrix based on synthetic octacalcium phosphate activated with plasmid deoxyribonucleic acid with genes of vascular endothelial growth factor.Materials and methods. Histomorphological examination of bone tissue biopsy of jaws was carried out in 50 patients of both genders, who needed additional volume of bone tissue to install dental implantation. Patients were divided into 2 groups by type of grafted material. 6 months after the surgery, bone biopsies were taken from the bone sites at the stage of implant placement. Histomorphological patterns and histomycrophotograms were studied in bone biopcies.Results. In bone tissue biopsies of patients implanted with a tissue engineering construct based on synthetic octacalcium phosphate activated with plasmid DNA with vascular endothelial growth factor gene, it was revealed that after 6 months there was prevaluation of mature bone tissue (42,71%), with the proportion of differentiated plate bone tissue being < 90%.Conclusions. Histomorphometric analysis showed that in patients implanted with a tissue engineering construct based on synthetic octacalcium phosphate activated with plasmid DNA with vascular endothelial growth factor gene, after 6 months, early rearrangement of bone tissue into a mechanically dense and highly mineralized structure was detected.
Effects of Vascular Endothelial Growth Factor 165 on Bone Tissue Engineering
